cyclophosphamide,fludarabine,lisocabtagene maraleucel
bms
['transcend,(-nhl-001),(-nhl 001),(-nhl001),(-nhl-006),(-nhl 006),(-nhl006),(-pilot-017006),(-pilot017006),(-pilot 017006)', 'transcend fl', 'liso-cel']
continued exciting liso-cel data from transcend fl showing high orr rates from these t-cell redirecting therapies in fl with long durations of response in 3l+ and acceptable/expected tox for this product in the 2l+ group #17icml 
Heme/Onc fellow @UCCancerCenter interested in aggressive lymphoma, novel therapeutics, and cellular therapies #lymsm #TcellRx. Views are my own.